Publications
American Society for Microbiology
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity
Although the live-attenuated measles virus (MeV) is one of the safest and most efficacious human vaccines, a measles-vectored COVID-19 vaccine candidate expressing the SARS-CoV-2 spike failed to elicit neutralizing antibody (nAb) responses in a phase-1 clinical trial, especially in measles-immune individuals.
Medical Life Sciences
Researchers generate a remodeled live-attenuated measles vaccine capable of driving nAb responses against SARS-CoV-2 spike protein
In a recent study researchers developed a measles virus (MeV)-vectored vaccine capable of inducing high neutralizing antibody (nAb) responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Naik et al.
Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
Mol Cancer Ther. 2018 Jan;17(1):316-326. doi: 10.
Lauro Velazquez-Salinas et al.
Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV
Hum Gene Ther Clin Dev. 2017 Jun 1; 28(2): 108–115.
Zhang et al.
Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model
Mol Ther. 2016 Dec; 24(12): 2109–2117.
LeBlanc et al.
Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
Hum Gene Ther Clin Dev. 2013 Dec;24(4):174-81. doi: 10.1089/humc.2013.165.
Naik et al.
Curative one-shot systemic virotherapy in murine myeloma
Leukemia. 2012 Aug;26(8):1870-8. doi: 10.1038/leu.2012.70. Epub 2012 Mar 19.